Aptose Biosciences Inc. (TSX: APS)

Aptose Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	13.62	15.59	14.51	19.46	26.48	10.02
Research & Development	34.4	36.77	28.09	45.99	29.29	16.84
Operating Expenses	48.02	52.36	42.6	65.45	55.77	26.86
Operating Income	-48.02	-52.36	-42.6	-65.45	-55.77	-26.86
Interest & Investment Income	0.85	1.15	0.79	0.09	0.52	0.57
Net Interest Expenses	0.85	1.15	0.79	0.09	0.52	0.57
Currency Exchange Gain (Loss)	-0	-0	-0.01	-0	0.01	0.01
EBT Excluding Unusual Items	-47.17	-51.21	-41.82	-65.35	-55.24	-26.28
Pretax Income	-47.17	-51.21	-41.82	-65.35	-55.24	-26.28
Net Income	-47.17	-51.21	-41.82	-65.35	-55.24	-26.28
Net Income to Common	-47.17	-51.21	-41.82	-65.35	-55.24	-26.28
Shares Outstanding (Basic)	8	7	6	6	5	3
Shares Outstanding (Diluted)	8	7	6	6	5	3
Shares Change (YoY)	37.99%	9.82%	3.57%	8.86%	63.15%	50.22%
EPS (Basic)	-5.55	-7.58	-6.80	-11.00	-10.12	-7.86
EPS (Diluted)	-5.55	-7.58	-6.80	-11.00	-10.12	-7.86
Free Cash Flow	-45.08	-44.62	-32.35	-43.52	-33.97	-21.66
Free Cash Flow Per Share	-5.31	-6.61	-5.26	-7.33	-6.23	-6.48
EBITDA	-47.94	-52.27	-42.48	-65.3	-55.62	-26.71
D&A For EBITDA	0.08	0.09	0.12	0.15	0.15	0.15
EBIT	-48.02	-52.36	-42.6	-65.45	-55.77	-26.86

Source: S&P Capital IQ. Standard template.